Analysis of selected genetic variants in psoriasis susceptibility and response to treatment

Damian Malinowski; Monika Białecka; Piotr Bojko; Adriana Kiszkielis; Marek Droździk; Mateusz Kurzawski

doi:10.5114/ada.2022.120885

Analysis of selected genetic variants in psoriasis susceptibility and response to treatment

Postepy Dermatol Alergol. 2022 Oct;39(5):934-939. doi: 10.5114/ada.2022.120885. Epub 2022 Nov 9.

Authors

Damian Malinowski¹, Monika Białecka¹, Piotr Bojko², Adriana Kiszkielis³, Marek Droździk⁴, Mateusz Kurzawski⁴

Affiliations

¹ Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland.
² Aesthetic Dermatology Centre "Hippocrates", Szczecin, Poland.
³ The 2 Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland.
⁴ Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland.

Abstract

Introduction: Aetiology of psoriasis is complex with risk factors involving both environmental triggers and genetic background. Although the best characterized genetic risk factor for psoriasis is HLA-C*06 allele, a number of other variants were associated with the disease.

Aim: In the current paper we have conducted a confirmation study for SNPs located in 9 gene regions in a case-control analysis of 507 psoriatic patients and 396 controls from the Polish population.

Material and methods: Subsequently the impact of genetic variants on response to topical and NB-UVB therapy (reduction in the Psoriasis Area and Severity Index) was analysed.

Results: Significant differences in genotype and/or allelic frequency were observed for the following SNPs: rs33980500 (TRAF3IP2), rs582757 (TNFAIP3I), rs12188300 (IL12B), rs28998802 (NOS2), and rs2233278 (TNIP1). None of the genetic factors was associated with treatment outcome.

Conclusions: Although the genetic variants have an impact on the disease risk, they are unlikely to be useful in personalization of topical therapy.

Keywords: NB-UVB; SNP; psoriasis.